Strengthening a culture dedicated to patients and equity: A conversation with Vas Narasimhan, CEO of Novartis

Stephen J. Ubl   |     March 31, 2021   |   SHARE THIS

This year our industry has been working around the clock to combat the COVID-19 virus, including developing effective therapeutics to treat COVID-19 and vaccines to prevent future infections. Outside of the novel coronavirus, major social issues have been brought to the forefront of public discourse. We understand that systemic racism is as real as any disease and our industry is not immune. We need to stand up to racism and injustice because failing to do so impacts our collective wellbeing. Our industry is committed to learning and leading us forward.

I had the opportunity to connect with Vas Narasimhan, CEO of Novartis, about the industry’s efforts in this space. See below for our conversation

As always, you can stay up-to-date with the work the biopharmaceutical industry is doing to advance equity here.

Stephen J. Ubl

Stephen J. Ubl Stephen J. Ubl is president and chief executive officer of PhRMA. Mr. Ubl leads PhRMA’s work preserving and strengthening a health care and economic environment that encourages medical innovation, new drug discovery and access to life-saving medicines. Ubl is recognized around the world as a leading health care advocate and policy expert who collaborates successfully with diverse stakeholder groups – including patient and physician groups, regulators, public and private payers, and global trade organizations – to help ensure timely patient access to innovative treatments and cures.

Search the Catalyst

View Posts by Topic

see all

View Posts by Contributor

View Posts by Date

see all

Subscribe to Email Updates